Skip to main navigation
Skip to search
Skip to main content
Tel Aviv University Home
Update Request & User Guide (TAU staff only)
Home
Experts
Research units
Research output
Datasets
Prizes
Activities
Press/Media
Search by expertise, name or affiliation
Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics
David Gurwitz
*
*
Corresponding author for this work
Human Molecular Genetics Biochemistry
Research output
:
Contribution to journal
›
Comment/debate
633
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Aggressiveness
50%
Angiotensin II Type 1 Receptor (AT1R)
50%
Angiotensin Receptor Blockers
100%
Angiotensin-converting Enzyme 2 (ACE2)
50%
AT1R Blockers
100%
Binding Site
50%
Clinical Patients
50%
Coronavirus COVID-19
50%
Coronavirus Outbreak
100%
COVID-19
100%
COVID-19 Outbreak
100%
Directional Dependence
50%
Fatality
50%
High Mortality Rate
50%
Immunization
50%
Influenza Virus Strain
50%
Losartan
50%
Medical Records
50%
Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
50%
New Coronavirus
50%
Rapid Spread
50%
SARS Epidemic
50%
SARS-CoV-2 Infection
50%
SARS-CoV-2 Virus
50%
SARS-CoV-2 Virus Infection
50%
Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)
100%
Viral
50%
Virus mutation
50%
Pharmacology, Toxicology and Pharmaceutical Science
Angiotensin 1 Receptor
14%
Angiotensin Converting Enzyme 2
14%
Angiotensin Receptor Antagonist
100%
Binding Site
14%
Coronavirinae
42%
Epidemic
57%
Fatality
14%
Infection
14%
Influenza Virus
14%
Losartan
14%
Middle East Respiratory Syndrome Coronavirus
14%
Mortality Rate
14%
SARS Coronavirus
100%
Severe Acute Respiratory Syndrome
14%
Virus Infection
14%
Virus Strain
14%